Egypt Pharmaceutical Market By Type (Pharmaceutical Drugs and Biologics), By Drug Classification (Branded Drugs and Generic Drugs), By Mode of Purchase (Prescription-Based Drugs and Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition, Forecast & Opportunities, 2019-2029F
Egypt Pharmaceutical Market was valued at USD 1204.09 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.45% through 2029. The Egypt pharmaceutical market is primarily driven by several key factors contributing to its growth and development. These include a large and growing population, increasing healthcare expenditure, government initiatives to improve healthcare infrastructure, and rising incidence of chronic and infectious diseases. Egypt's strategic geographic location and its role as a regional hub for pharmaceutical production and distribution also play significant roles in driving market expansion. Reforms aimed at enhancing regulatory frameworks and fostering innovation within the pharmaceutical sector contribute to attracting investment and advancing healthcare standards. The market's resilience and potential for growth are further supported by a growing middle class with greater access to healthcare services and a rising demand for high-quality pharmaceutical products across various therapeutic areas.
Key Market Drivers
Growing Population
Egypt's population growth has surpassed 100 million, positioning the country as a significant market for pharmaceutical products. This demographic trend underscores a rising demand for healthcare services and medications tailored to address diverse health conditions prevalent among various demographic groups. With a larger and expanding population, there is an increasing need for pharmaceutical solutions that cater to the healthcare needs of Egyptians across different age groups, socio-economic backgrounds, and geographic regions.
The demographic diversity within Egypt contributes to a multifaceted demand for medications ranging from treatments for chronic diseases like cardiovascular ailments, diabetes, and cancer, to medications addressing acute conditions and infectious diseases prevalent in urban and rural settings alike. This growing population also drives demand for specialized pharmaceutical products that cater to specific health challenges faced by different segments of society, from infants and children to elderly adults. The expanding population size amplifies the necessity for continuous innovation in pharmaceutical research and development to introduce new therapies, improve existing treatments, and enhance healthcare outcomes nationwide. This demographic dynamism underscores Egypt's role as a pivotal market for pharmaceutical companies aiming to provide accessible, effective, and high-quality healthcare solutions to meet the evolving needs of its diverse population.
Increasing Healthcare Expenditure
The Egyptian government has undertaken substantial efforts to bolster its healthcare sector by progressively augmenting healthcare expenditure. This strategic increase is aimed at fortifying healthcare infrastructure, broadening the reach of healthcare services, and subsidizing essential medicines across the nation. The enhanced financial commitment to healthcare initiatives plays a pivotal role in fostering market growth by enhancing affordability and accessibility of healthcare services for the Egyptian population.
Through targeted investments, the government aims to upgrade and expand healthcare facilities, including hospitals, clinics, and medical centers, particularly in underserved rural areas and urban centers experiencing rapid population growth. These improvements aim to bridge gaps in healthcare access, ensuring that a larger segment of the population can avail themselves of critical medical services and treatments. Increased funding supports initiatives to subsidize essential medicines, making them more affordable and accessible to patients. This measure is crucial in addressing healthcare disparities and ensuring that individuals from all socio-economic backgrounds can afford necessary medications for chronic diseases, acute illnesses, and preventive care.
Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer represents a significant driver for the pharmaceutical industry in Egypt. This rise in chronic conditions is influenced by several interconnected factors, including shifting lifestyles, rapid urbanization, and an aging population.
Lifestyle changes, characterized by sedentary lifestyles, unhealthy dietary habits, and higher stress levels, contribute to the escalation of chronic diseases. These factors are often associated with urbanization, where populations experience shifts from traditional dietary patterns and physical activity to more modern, convenience-oriented lifestyles. Urban areas also tend to have higher concentrations of environmental pollutants and industrialization, which can exacerbate health risks and contribute to the prevalence of chronic conditions. Egypt, like many other countries, is experiencing demographic shifts characterized by an aging population. As life expectancy increases and healthcare improves, there is a corresponding rise in age-related chronic diseases such as cardiovascular diseases and diabetes. These conditions require ongoing management and treatment, driving sustained demand for pharmaceutical products that address symptoms, manage complications, and improve quality of life for affected individuals.
Government Initiatives and Regulatory Reforms
Government initiatives aimed at reforming Egypt's pharmaceutical sector play a crucial role in driving market expansion and enhancing healthcare outcomes across the country. These initiatives encompass a range of strategic measures designed to reform regulatory frameworks, promote local production, and attract investment in the pharmaceutical industry. In November 2022, Astellas Pharma Inc., a global pharmaceutical company dedicated to translating innovative science into patient value, has officially inaugurated its new Scientific Office in Cairo. The company's strategic focus includes prioritizing future product launches and expanding indications for medications in Egypt. This initiative encompasses advancing oncology treatments targeting diseases such as Acute Myeloid Leukaemia (AML), Urothelial Cancer, and Gastric Cancer. Astellas plans to introduce medications for managing anaemia in chronic kidney disease patients, alongside advancements in regenerative medicine and gene therapy technologies.
Key Market Challenges
Regulatory Environment and Compliance
The regulatory framework in Egypt's pharmaceutical sector presents a significant challenge, characterized by bureaucratic processes, inconsistent enforcement, and delays in approvals. Pharmaceutical companies often encounter challenges navigating the complex regulatory landscape, which can hinder the timely launch of new drugs and innovations. Lack of transparency and unpredictability in regulatory decisions further exacerbate compliance issues, impacting market competitiveness and investment attractiveness. Efforts to streamline regulatory procedures and enhance transparency are essential to facilitate smoother market operations and foster industry growth.
Counterfeit Medicines and Quality Control
Counterfeit medicines pose a persistent challenge in Egypt, threatening patient safety, undermining trust in healthcare providers, and affecting market integrity. The prevalence of counterfeit drugs, including substandard and falsified products, remains a concern despite regulatory efforts to combat illicit practices. Ensuring stringent quality control measures throughout the supply chain is crucial to safeguarding public health and maintaining the reputation of pharmaceutical products. Collaboration between regulatory authorities, law enforcement agencies, and industry stakeholders is essential to mitigate the impact of counterfeit medicines on the market and protect patient welfare.
Price Controls and Affordability
Price controls imposed by the Egyptian government on pharmaceutical products aim to enhance affordability and access to essential medicines. However, these controls can create challenges for pharmaceutical companies, particularly in maintaining profitability and sustaining investment in research and development. Price regulations may limit market incentives for innovation and hinder the introduction of new therapies and technologies. Balancing affordability with sustainability in the pharmaceutical market requires a comprehensive approach that considers the needs of both patients and industry stakeholders while ensuring equitable access to healthcare.
Key Market Trends
Investment in Pharmaceutical Infrastructure
Continuous investments in Egypt's pharmaceutical sector are pivotal in enhancing the industry's capacity, capability, and overall competitiveness. These investments span across various critical areas including pharmaceutical manufacturing facilities, research and development (R&D) centers, and distribution networks. In May 2021, Egypt inaugurated Gypto Pharma City, a newly established industrial zone exclusively dedicated to the healthcare sector. Situated 30 kilometers north of Cairo and spanning 180,000 square meters, it stands as one of the largest pharmaceutical production facilities in the Middle East. According to government reports, Gypto Pharma City houses 160 production lines capable of manufacturing 150 different types of medications, with an annual production capacity exceeding 150 million packages. This state-driven initiative aims to curtail Egypt's reliance on pharmaceutical imports and achieve greater self-sufficiency in healthcare manufacturing.
Pharmaceutical manufacturing facilities are key components of the sector's infrastructure. Investments in these facilities focus on upgrading existing infrastructure and establishing new state-of-the-art plants. Modern manufacturing facilities equipped with advanced technology and automation systems enhance production efficiency, increase output capacity, and ensure adherence to international quality standards. This not only boosts the availability of pharmaceutical products but also supports the local economy by creating jobs and fostering industrial growth. Research and development centers play a crucial role in driving innovation within the pharmaceutical sector. Investments in R&D facilities facilitate the discovery of new drugs, formulation improvements, and the development of novel treatment options tailored to address local healthcare needs. Collaborative efforts between academia, research institutions, and pharmaceutical companies further accelerate innovation, bringing advanced therapies and medicines to market faster.
Technological Advancements and Innovation
Advancements in pharmaceutical technology represent a transformative force driving innovation and growth within Egypt's healthcare sector. Key technological advancements include biotechnology, personalized medicine, and digital health solutions, each contributing uniquely to the development of new drugs, therapies, and diagnostic tools.
Biotechnology has revolutionized drug development by enabling the creation of biologics, vaccines, and gene therapies tailored to target specific diseases and conditions. This approach allows for more precise treatment options that are often more effective and have fewer side effects compared to traditional pharmaceuticals. Biotechnological innovations also facilitate the production of biosimilars, which are cost-effective alternatives to expensive biologic drugs, enhancing affordability and accessibility for patients. Personalized medicine, another significant advancement, emphasizes the customization of healthcare based on individual genetic, environmental, and lifestyle factors. By leveraging technologies such as genetic testing and biomarker analysis, healthcare providers can tailor treatment plans to each patient's unique profile, optimizing therapeutic outcomes and minimizing adverse reactions. This personalized approach not only improves patient care but also enhances patient compliance and overall healthcare efficiency.
Segmental Insights
Type Insights
Based on the Type, pharmaceutical drugs have traditionally held a dominant position compared to biologics. This dominance can be attributed to several factors that shape the market landscape. Pharmaceutical drugs encompass a wide range of formulations, including tablets, capsules, and injectables, which are well-established and familiar to healthcare providers and patients alike. These formulations are often more affordable and easier to manufacture and distribute compared to biologics, which are typically complex proteins derived from living organisms.
Regulatory frameworks in Egypt have historically been more conducive to the approval and market entry of pharmaceutical drugs compared to biologics. The approval process for biologics involves rigorous scrutiny and requires specialized manufacturing capabilities and expertise, which may pose challenges in a market where infrastructure and resources for biologics production are developing. Affordability also plays a crucial role in shaping the dominance of pharmaceutical drugs in the market. Egypt's population has a significant proportion of individuals with limited purchasing power, and pharmaceutical drugs generally offer more cost-effective treatment options compared to biologics, which tend to be more expensive due to their complex manufacturing processes and specialized handling requirements.
Drug Classification Insights
Based on the Drug Classification, generic drugs have established a dominant presence compared to branded drugs for several compelling reasons. Generic drugs are bioequivalent to their branded counterparts, meaning they contain the same active ingredients in the same dosage form and are administered via the same route of administration. This ensures therapeutic equivalence and efficacy, assuring healthcare providers and patients of their effectiveness.
Cost considerations play a significant role in the dominance of generic drugs. Egypt has a large population with diverse socioeconomic backgrounds, and affordability of healthcare is a crucial factor for access to essential medications. Generic drugs typically cost significantly less than branded drugs because they do not involve the same extensive research and development costs, marketing expenses, or patent protection fees as branded counterparts. This affordability makes generic drugs more accessible to a broader segment of the population, particularly those with limited financial means or those covered by public health insurance schemes. Government policies and healthcare initiatives in Egypt actively promote the use of generic drugs. Policies such as generic substitution encourage healthcare providers to prescribe and dispense generic equivalents when available, further driving their adoption in clinical practice. These policies aim to reduce healthcare expenditures, improve medication adherence, and enhance overall healthcare affordability and accessibility.
Regional Insights
Cairo, as the capital and largest city of Egypt, holds a dominant position in the country's pharmaceutical market for several key reasons. Cairo's status as the economic, cultural, and political center of Egypt translates into a concentration of healthcare infrastructure, pharmaceutical companies, and healthcare professionals. The city boasts numerous hospitals, clinics, pharmacies, and healthcare facilities that cater to a large and diverse population base.
One of the primary factors contributing to Cairo's dominance in the pharmaceutical market is its extensive healthcare infrastructure. The city is home to major hospitals and healthcare centers that serve as primary distribution points for pharmaceutical products. These facilities not only provide essential medical services but also act as hubs for prescribing and dispensing medications, including both branded and generic drugs. Cairo's dense population plays a significant role in driving pharmaceutical consumption. With millions of residents and a steady influx of visitors from other parts of Egypt seeking medical treatment, the demand for pharmaceutical products is consistently high. This population density creates a robust market for a wide range of medications, from everyday over-the-counter drugs to specialized treatments for chronic and acute conditions.
Key Market Players
In this report, the Egypt Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Egypt Pharmaceutical Market.
Available Customizations:
Egypt Pharmaceutical Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Growing Population
Egypt's population growth has surpassed 100 million, positioning the country as a significant market for pharmaceutical products. This demographic trend underscores a rising demand for healthcare services and medications tailored to address diverse health conditions prevalent among various demographic groups. With a larger and expanding population, there is an increasing need for pharmaceutical solutions that cater to the healthcare needs of Egyptians across different age groups, socio-economic backgrounds, and geographic regions.
The demographic diversity within Egypt contributes to a multifaceted demand for medications ranging from treatments for chronic diseases like cardiovascular ailments, diabetes, and cancer, to medications addressing acute conditions and infectious diseases prevalent in urban and rural settings alike. This growing population also drives demand for specialized pharmaceutical products that cater to specific health challenges faced by different segments of society, from infants and children to elderly adults. The expanding population size amplifies the necessity for continuous innovation in pharmaceutical research and development to introduce new therapies, improve existing treatments, and enhance healthcare outcomes nationwide. This demographic dynamism underscores Egypt's role as a pivotal market for pharmaceutical companies aiming to provide accessible, effective, and high-quality healthcare solutions to meet the evolving needs of its diverse population.
Increasing Healthcare Expenditure
The Egyptian government has undertaken substantial efforts to bolster its healthcare sector by progressively augmenting healthcare expenditure. This strategic increase is aimed at fortifying healthcare infrastructure, broadening the reach of healthcare services, and subsidizing essential medicines across the nation. The enhanced financial commitment to healthcare initiatives plays a pivotal role in fostering market growth by enhancing affordability and accessibility of healthcare services for the Egyptian population.
Through targeted investments, the government aims to upgrade and expand healthcare facilities, including hospitals, clinics, and medical centers, particularly in underserved rural areas and urban centers experiencing rapid population growth. These improvements aim to bridge gaps in healthcare access, ensuring that a larger segment of the population can avail themselves of critical medical services and treatments. Increased funding supports initiatives to subsidize essential medicines, making them more affordable and accessible to patients. This measure is crucial in addressing healthcare disparities and ensuring that individuals from all socio-economic backgrounds can afford necessary medications for chronic diseases, acute illnesses, and preventive care.
Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer represents a significant driver for the pharmaceutical industry in Egypt. This rise in chronic conditions is influenced by several interconnected factors, including shifting lifestyles, rapid urbanization, and an aging population.
Lifestyle changes, characterized by sedentary lifestyles, unhealthy dietary habits, and higher stress levels, contribute to the escalation of chronic diseases. These factors are often associated with urbanization, where populations experience shifts from traditional dietary patterns and physical activity to more modern, convenience-oriented lifestyles. Urban areas also tend to have higher concentrations of environmental pollutants and industrialization, which can exacerbate health risks and contribute to the prevalence of chronic conditions. Egypt, like many other countries, is experiencing demographic shifts characterized by an aging population. As life expectancy increases and healthcare improves, there is a corresponding rise in age-related chronic diseases such as cardiovascular diseases and diabetes. These conditions require ongoing management and treatment, driving sustained demand for pharmaceutical products that address symptoms, manage complications, and improve quality of life for affected individuals.
Government Initiatives and Regulatory Reforms
Government initiatives aimed at reforming Egypt's pharmaceutical sector play a crucial role in driving market expansion and enhancing healthcare outcomes across the country. These initiatives encompass a range of strategic measures designed to reform regulatory frameworks, promote local production, and attract investment in the pharmaceutical industry. In November 2022, Astellas Pharma Inc., a global pharmaceutical company dedicated to translating innovative science into patient value, has officially inaugurated its new Scientific Office in Cairo. The company's strategic focus includes prioritizing future product launches and expanding indications for medications in Egypt. This initiative encompasses advancing oncology treatments targeting diseases such as Acute Myeloid Leukaemia (AML), Urothelial Cancer, and Gastric Cancer. Astellas plans to introduce medications for managing anaemia in chronic kidney disease patients, alongside advancements in regenerative medicine and gene therapy technologies.
Key Market Challenges
Regulatory Environment and Compliance
The regulatory framework in Egypt's pharmaceutical sector presents a significant challenge, characterized by bureaucratic processes, inconsistent enforcement, and delays in approvals. Pharmaceutical companies often encounter challenges navigating the complex regulatory landscape, which can hinder the timely launch of new drugs and innovations. Lack of transparency and unpredictability in regulatory decisions further exacerbate compliance issues, impacting market competitiveness and investment attractiveness. Efforts to streamline regulatory procedures and enhance transparency are essential to facilitate smoother market operations and foster industry growth.
Counterfeit Medicines and Quality Control
Counterfeit medicines pose a persistent challenge in Egypt, threatening patient safety, undermining trust in healthcare providers, and affecting market integrity. The prevalence of counterfeit drugs, including substandard and falsified products, remains a concern despite regulatory efforts to combat illicit practices. Ensuring stringent quality control measures throughout the supply chain is crucial to safeguarding public health and maintaining the reputation of pharmaceutical products. Collaboration between regulatory authorities, law enforcement agencies, and industry stakeholders is essential to mitigate the impact of counterfeit medicines on the market and protect patient welfare.
Price Controls and Affordability
Price controls imposed by the Egyptian government on pharmaceutical products aim to enhance affordability and access to essential medicines. However, these controls can create challenges for pharmaceutical companies, particularly in maintaining profitability and sustaining investment in research and development. Price regulations may limit market incentives for innovation and hinder the introduction of new therapies and technologies. Balancing affordability with sustainability in the pharmaceutical market requires a comprehensive approach that considers the needs of both patients and industry stakeholders while ensuring equitable access to healthcare.
Key Market Trends
Investment in Pharmaceutical Infrastructure
Continuous investments in Egypt's pharmaceutical sector are pivotal in enhancing the industry's capacity, capability, and overall competitiveness. These investments span across various critical areas including pharmaceutical manufacturing facilities, research and development (R&D) centers, and distribution networks. In May 2021, Egypt inaugurated Gypto Pharma City, a newly established industrial zone exclusively dedicated to the healthcare sector. Situated 30 kilometers north of Cairo and spanning 180,000 square meters, it stands as one of the largest pharmaceutical production facilities in the Middle East. According to government reports, Gypto Pharma City houses 160 production lines capable of manufacturing 150 different types of medications, with an annual production capacity exceeding 150 million packages. This state-driven initiative aims to curtail Egypt's reliance on pharmaceutical imports and achieve greater self-sufficiency in healthcare manufacturing.
Pharmaceutical manufacturing facilities are key components of the sector's infrastructure. Investments in these facilities focus on upgrading existing infrastructure and establishing new state-of-the-art plants. Modern manufacturing facilities equipped with advanced technology and automation systems enhance production efficiency, increase output capacity, and ensure adherence to international quality standards. This not only boosts the availability of pharmaceutical products but also supports the local economy by creating jobs and fostering industrial growth. Research and development centers play a crucial role in driving innovation within the pharmaceutical sector. Investments in R&D facilities facilitate the discovery of new drugs, formulation improvements, and the development of novel treatment options tailored to address local healthcare needs. Collaborative efforts between academia, research institutions, and pharmaceutical companies further accelerate innovation, bringing advanced therapies and medicines to market faster.
Technological Advancements and Innovation
Advancements in pharmaceutical technology represent a transformative force driving innovation and growth within Egypt's healthcare sector. Key technological advancements include biotechnology, personalized medicine, and digital health solutions, each contributing uniquely to the development of new drugs, therapies, and diagnostic tools.
Biotechnology has revolutionized drug development by enabling the creation of biologics, vaccines, and gene therapies tailored to target specific diseases and conditions. This approach allows for more precise treatment options that are often more effective and have fewer side effects compared to traditional pharmaceuticals. Biotechnological innovations also facilitate the production of biosimilars, which are cost-effective alternatives to expensive biologic drugs, enhancing affordability and accessibility for patients. Personalized medicine, another significant advancement, emphasizes the customization of healthcare based on individual genetic, environmental, and lifestyle factors. By leveraging technologies such as genetic testing and biomarker analysis, healthcare providers can tailor treatment plans to each patient's unique profile, optimizing therapeutic outcomes and minimizing adverse reactions. This personalized approach not only improves patient care but also enhances patient compliance and overall healthcare efficiency.
Segmental Insights
Type Insights
Based on the Type, pharmaceutical drugs have traditionally held a dominant position compared to biologics. This dominance can be attributed to several factors that shape the market landscape. Pharmaceutical drugs encompass a wide range of formulations, including tablets, capsules, and injectables, which are well-established and familiar to healthcare providers and patients alike. These formulations are often more affordable and easier to manufacture and distribute compared to biologics, which are typically complex proteins derived from living organisms.
Regulatory frameworks in Egypt have historically been more conducive to the approval and market entry of pharmaceutical drugs compared to biologics. The approval process for biologics involves rigorous scrutiny and requires specialized manufacturing capabilities and expertise, which may pose challenges in a market where infrastructure and resources for biologics production are developing. Affordability also plays a crucial role in shaping the dominance of pharmaceutical drugs in the market. Egypt's population has a significant proportion of individuals with limited purchasing power, and pharmaceutical drugs generally offer more cost-effective treatment options compared to biologics, which tend to be more expensive due to their complex manufacturing processes and specialized handling requirements.
Drug Classification Insights
Based on the Drug Classification, generic drugs have established a dominant presence compared to branded drugs for several compelling reasons. Generic drugs are bioequivalent to their branded counterparts, meaning they contain the same active ingredients in the same dosage form and are administered via the same route of administration. This ensures therapeutic equivalence and efficacy, assuring healthcare providers and patients of their effectiveness.
Cost considerations play a significant role in the dominance of generic drugs. Egypt has a large population with diverse socioeconomic backgrounds, and affordability of healthcare is a crucial factor for access to essential medications. Generic drugs typically cost significantly less than branded drugs because they do not involve the same extensive research and development costs, marketing expenses, or patent protection fees as branded counterparts. This affordability makes generic drugs more accessible to a broader segment of the population, particularly those with limited financial means or those covered by public health insurance schemes. Government policies and healthcare initiatives in Egypt actively promote the use of generic drugs. Policies such as generic substitution encourage healthcare providers to prescribe and dispense generic equivalents when available, further driving their adoption in clinical practice. These policies aim to reduce healthcare expenditures, improve medication adherence, and enhance overall healthcare affordability and accessibility.
Regional Insights
Cairo, as the capital and largest city of Egypt, holds a dominant position in the country's pharmaceutical market for several key reasons. Cairo's status as the economic, cultural, and political center of Egypt translates into a concentration of healthcare infrastructure, pharmaceutical companies, and healthcare professionals. The city boasts numerous hospitals, clinics, pharmacies, and healthcare facilities that cater to a large and diverse population base.
One of the primary factors contributing to Cairo's dominance in the pharmaceutical market is its extensive healthcare infrastructure. The city is home to major hospitals and healthcare centers that serve as primary distribution points for pharmaceutical products. These facilities not only provide essential medical services but also act as hubs for prescribing and dispensing medications, including both branded and generic drugs. Cairo's dense population plays a significant role in driving pharmaceutical consumption. With millions of residents and a steady influx of visitors from other parts of Egypt seeking medical treatment, the demand for pharmaceutical products is consistently high. This population density creates a robust market for a wide range of medications, from everyday over-the-counter drugs to specialized treatments for chronic and acute conditions.
Key Market Players
- MDI Pharma
- Merck Ltd.
- Novartis Egypt
- Pharco Pharmaceuticals
- Roche Egypt
- Sanofi Egypt
- EVA Pharma
- Orchidia Pharmaceutical Industries
- GlaxoSmithKline Egypt
- Tabuk Pharmaceuticals Egypt
In this report, the Egypt Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Egypt Pharmaceutical Market, By Type:
- Pharmaceutical Drugs
- Biologics
- Egypt Pharmaceutical Market, By Drug Classification:
- Branded Drugs
- Generic Drugs
- Egypt Pharmaceutical Market, By Mode of Purchase:
- Prescription-Based Drugs
- Over-the-counter Drugs
- Egypt Pharmaceutical Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Egypt Pharmaceutical Market, By Region:
- Cairo
- Alexandria
- Giza
- Qalyubia
- Port Said
- Suez
- Rest of Egypt
Company Profiles: Detailed analysis of the major companies present in the Egypt Pharmaceutical Market.
Available Customizations:
Egypt Pharmaceutical Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EGYPT PHARMACEUTICAL MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Pharmaceutical Drugs and Biologics)
5.2.1.1. By Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others)
5.2.1.2. By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)
5.2.2. By Drug Classification (Branded Drugs and Generic Drugs)
5.2.3. By Mode of Purchase (Prescription-Based Drugs and Over-the-counter Drugs)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2023)
5.3. Market Map
6. EGYPT BRANDED DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Mode of Purchase
6.2.3. By Distribution Channel
7. EGYPT GENERIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Mode of Purchase
7.2.3. By Distribution Channel
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Merger & Acquisition (If Any)
9.2. Product Launches (If Any)
9.3. Recent Developments
10. EGYPT ECONOMIC PROFILE
11. EGYPT PHARMACEUTICAL MARKET: SWOT ANALYSIS
12. PORTER’S FIVE FORCES ANALYSIS
12.1. Competition in the Industry
12.2. Potential of New Entrants
12.3. Power of Suppliers
12.4. Power of Customers
12.5. Threat of Substitute Products
13. COMPETITIVE LANDSCAPE
13.1. MDI Pharma
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Financials (As Reported)
13.1.5. Recent Developments
13.1.6. Key Personnel Details
13.1.7. SWOT Analysis
13.2. Merck Ltd.
13.3. Novartis Egypt
13.4. Pharco Pharmaceuticals
13.5. Roche Egypt
13.6. Sanofi Egypt
13.7. EVA Pharma
13.8. Orchidia Pharmaceutical Industries
13.9. GlaxoSmithKline Egypt
13.10. Tabuk Pharmaceuticals Egypt
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. EGYPT PHARMACEUTICAL MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Pharmaceutical Drugs and Biologics)
5.2.1.1. By Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others)
5.2.1.2. By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)
5.2.2. By Drug Classification (Branded Drugs and Generic Drugs)
5.2.3. By Mode of Purchase (Prescription-Based Drugs and Over-the-counter Drugs)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2023)
5.3. Market Map
6. EGYPT BRANDED DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Mode of Purchase
6.2.3. By Distribution Channel
7. EGYPT GENERIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Mode of Purchase
7.2.3. By Distribution Channel
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Merger & Acquisition (If Any)
9.2. Product Launches (If Any)
9.3. Recent Developments
10. EGYPT ECONOMIC PROFILE
11. EGYPT PHARMACEUTICAL MARKET: SWOT ANALYSIS
12. PORTER’S FIVE FORCES ANALYSIS
12.1. Competition in the Industry
12.2. Potential of New Entrants
12.3. Power of Suppliers
12.4. Power of Customers
12.5. Threat of Substitute Products
13. COMPETITIVE LANDSCAPE
13.1. MDI Pharma
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Financials (As Reported)
13.1.5. Recent Developments
13.1.6. Key Personnel Details
13.1.7. SWOT Analysis
13.2. Merck Ltd.
13.3. Novartis Egypt
13.4. Pharco Pharmaceuticals
13.5. Roche Egypt
13.6. Sanofi Egypt
13.7. EVA Pharma
13.8. Orchidia Pharmaceutical Industries
13.9. GlaxoSmithKline Egypt
13.10. Tabuk Pharmaceuticals Egypt
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
